USPIO contrast enhancement results from intracellular trapping of the iron particles in reactive cells, especially macrophages. 17FDG-PET studies have demonstrated that macrophages are present in spine infectious diseases but are absent in spine degenerative diseases. The aim of this work is to compare the enhancement induced by CLIAVIST in both diseases. The absence of macrophages in degenerative lesions should help to differentiate them from infectious lesions, who should present contrast enhancement in relation to the presence of macrophages.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Enrollment
40
Injection of 0,9 mL (weight \< 60kg) or 1,4 mL (weight \> 60kg) of Cliavist (ferucarbotran) by direct intraveinous way, 48 h following the MRI done with gadolinium.
Service de Neuroradiologie - Hôpital Central
Nancy, France
NOT_YET_RECRUITINGNouvel Hôpital Civil
Strasbourg, France
NOT_YET_RECRUITINGService de Radiologie 2 - Hôpital de Hautepierre
Strasbourg, France
RECRUITINGFirst MRI: performed immediately after gadolinium administration
Time frame: immediately after gadolinium administration
Second MRI: performed 24 hours after cliavist administration
Time frame: 24 hours after cliavist administration
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Service de Rhumatologie - Hôpital de Hautepierre
Strasbourg, France
NOT_YET_RECRUITING